• Gene Regulatory Networks Reveal Drivers of Neuronal Conversi

  2026-04-22

  Li et al. (2025) pioneered a systems biology approach using gene regulatory network (GRN) analysis to identify OTX2 and LMX1A as critical transcription factors in human fibroblast-to-neuron transdifferentiation. Their findings clarify molecular mechanisms underlying direct neuronal conversion, which is crucial for optimizing cell fate reprogramming in disease modeling and regenerative research.

• Cefotaxime in Antimicrobial Resistance Research: Protocols &

  2026-04-22

  Cefotaxime, a third-generation cephalosporin antibiotic, stands out in antimicrobial resistance research for its robust beta-lactamase resistance and reproducible efficacy in both Gram-positive and Gram-negative bacterial models. This article delivers actionable workflows, comparative data, and troubleshooting tips to help researchers maximize the utility of Cefotaxime in complex infection studies.

• 7-Ethyl-10-hydroxycamptothecin: Advanced Workflows in Colon

  2026-04-21

  Leverage 7-Ethyl-10-hydroxycamptothecin’s dual action for unmatched assay reliability in metastatic colon cancer models. This article delivers stepwise workflow enhancements, troubleshooting strategies, and highlights from recent mechanistic breakthroughs to elevate your topoisomerase I and FUBP1 pathway research.

• (S)-(+)-Ibuprofen (SKU B1018): Reliable COX Inhibition in Ce

  2026-04-21

  This scenario-driven article addresses real laboratory challenges in cell viability and inflammation assays, demonstrating how (S)-(+)-Ibuprofen (SKU B1018) from APExBIO delivers reproducible, high-purity, and cost-effective solutions. Researchers will find evidence-backed guidance for protocol optimization, data interpretation, and product selection, with clear references and actionable recommendations.

• Gemcitabine for DNA Damage Response and Apoptosis Assays

  2026-04-20

  Gemcitabine (4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one) is a benchmark DNA synthesis inhibitor that empowers robust, reproducible apoptosis and DNA damage response assays. This guide delivers actionable experimental workflows, advanced troubleshooting, and a cross-study perspective on optimizing Gemcitabine-based cancer research models.

• AP20187: Chemical Inducer of Dimerization for Regulated Cell

  2026-04-20

  AP20187 empowers researchers to orchestrate precise protein dimerization, enabling robust and tunable control of gene expression and signaling in living systems. With high solubility and proven in vivo efficacy, AP20187 accelerates conditional gene therapy and metabolic engineering workflows, while dedicated troubleshooting guidance ensures reproducible results.

• RAB31 Defines an ESCRT-Independent Exosome Pathway via Floti

  2026-04-19

  This article reviews a landmark study revealing how RAB31, phosphorylated by EGFR, regulates an ESCRT-independent pathway for exosome biogenesis. The findings provide mechanistic insights into exosome formation, cargo sorting, and the suppression of lysosomal degradation, with implications for understanding cell communication and disease progression.

• CD28-ARS2 Axis Drives PKM Splicing and Metabolic Flexibility

  2026-04-18

  This study reveals that CD28 signaling via the ARS2 adaptor drives extensive alternative splicing in activated CD8+ T cells, selectively promoting the PKM2 isoform to enhance glycolytic flexibility and antitumor function. These insights clarify immunometabolic reprogramming mechanisms, informing experimental approaches for TCA cycle enzyme and oxidative stress assays.

• Dacarbazine: Strategic Insights for Translational Oncology

  2026-04-17

  This thought-leadership article integrates mechanistic, experimental, and translational perspectives to provide advanced guidance for researchers leveraging Dacarbazine in cancer therapy. Drawing on the latest systems biology approaches and referencing state-of-the-art in vitro evaluation frameworks, the article offers both practical and visionary strategies for maximizing the clinical and research value of this antineoplastic chemotherapy drug.

• MK-2206 dihydrochloride: Applied Workflows for PI3K/Akt/mTOR

  2026-04-16

  MK-2206 dihydrochloride enables researchers to precisely inhibit Akt phosphorylation, facilitating robust apoptosis assays and pathway modulation in cancer and endometriosis models. Advanced workflows, troubleshooting guidance, and cross-study evidence position this inhibitor as a cornerstone for reproducible, mechanism-driven discoveries.

• Gemcitabine (A8437): Reliable DNA Synthesis Inhibition in Ca

  2026-04-15

  This article delivers a scenario-driven, evidence-based exploration of Gemcitabine (SKU A8437) for apoptosis and DNA damage response assays. Emphasizing real laboratory pain points and best practices, it demonstrates how Gemcitabine ensures reproducible, quantitative results and addresses vendor selection with scientific rigor.

• Nuclear cGAS Restricts L1 Retrotransposition via CHK2-TRIM41

  2026-04-14

  This study elucidates a novel posttranslational mechanism by which nuclear cGAS suppresses LINE-1 (L1) retrotransposition, safeguarding genome stability through CHK2-dependent phosphorylation and TRIM41-mediated degradation of L1 ORF2p. These findings offer new insights into the DNA damage response and may inform both cancer and aging research.

• Comparative Antibacterial Activities of β-Lactam Derivatives

  2026-04-13

  This study systematically compared the efficacy of N-formimidoyl thienamycin (MK0787) with several advanced β-lactam antibiotics, including ampicillin, against a diverse panel of resistant clinical isolates. It revealed nuanced activity profiles across major Gram-negative and Gram-positive pathogens, informing both mechanistic understanding and antibiotic resistance research priorities.

• One-step TUNEL Cy5 Apoptosis Detection Kit: Mechanisms and A

  2026-04-13

  Discover the scientific depth and precision of the One-step TUNEL Cy5 Apoptosis Detection Kit for sensitive apoptosis detection. This article uniquely bridges metabolic-immune insights and protocol optimization, offering a fresh perspective for advanced programmed cell death research.

• KPT-330 (Selinexor): Optimizing CRM1 Inhibition in Cancer Re

  2026-04-12

  KPT-330 (Selinexor) empowers cancer researchers with a highly selective, orally bioavailable CRM1 inhibitor, enabling robust apoptosis induction and tumor growth suppression in challenging cancer models. This guide synthesizes cutting-edge workflows, troubleshooting tactics, and practical parameters, translating reference breakthroughs into actionable laboratory strategies.

15080 records 1/1006 page Next 12345 下5页 Last page